Danaher Corporation $DHR Shares Sold by Dakota Wealth Management

Dakota Wealth Management cut its holdings in shares of Danaher Corporation (NYSE:DHR) by 60.7% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,880 shares of the conglomerate’s stock after selling 4,449 shares during the period. Dakota Wealth Management’s holdings in Danaher were worth $571,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also modified their holdings of the company. WFA of San Diego LLC purchased a new position in Danaher in the second quarter valued at about $26,000. Howard Hughes Medical Institute acquired a new position in shares of Danaher in the 2nd quarter valued at approximately $27,000. ANTIPODES PARTNERS Ltd purchased a new position in shares of Danaher during the 3rd quarter valued at approximately $27,000. TruNorth Capital Management LLC acquired a new stake in shares of Danaher during the third quarter worth approximately $28,000. Finally, Tripletail Wealth Management LLC bought a new stake in shares of Danaher in the third quarter worth $31,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Stock Performance

DHR stock opened at $209.35 on Friday. The company has a market capitalization of $148.04 billion, a P/E ratio of 41.54, a PEG ratio of 2.83 and a beta of 0.91. The company has a quick ratio of 1.51, a current ratio of 1.87 and a debt-to-equity ratio of 0.35. The company has a 50-day simple moving average of $225.62 and a 200 day simple moving average of $216.09. Danaher Corporation has a fifty-two week low of $171.00 and a fifty-two week high of $242.80.

Danaher (NYSE:DHR) last issued its quarterly earnings results on Tuesday, January 27th. The conglomerate reported $2.23 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.14 by $0.09. Danaher had a return on equity of 10.81% and a net margin of 14.71%.The firm had revenue of $6.84 billion during the quarter, compared to analyst estimates of $6.79 billion. During the same period last year, the company posted $2.14 EPS. The firm’s quarterly revenue was up 4.6% on a year-over-year basis. Sell-side analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, April 24th. Shareholders of record on Friday, March 27th will be issued a $0.40 dividend. This is an increase from Danaher’s previous quarterly dividend of $0.32. This represents a $1.60 annualized dividend and a dividend yield of 0.8%. The ex-dividend date of this dividend is Friday, March 27th. Danaher’s dividend payout ratio is currently 25.40%.

Insider Activity at Danaher

In other news, EVP Gregory M. Milosevich sold 1,320 shares of the business’s stock in a transaction on Thursday, February 19th. The stock was sold at an average price of $208.01, for a total transaction of $274,573.20. Following the sale, the executive vice president directly owned 5,099 shares of the company’s stock, valued at $1,060,642.99. The trade was a 20.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 11.10% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating on shares of Danaher in a research note on Thursday, January 29th. Evercore reaffirmed an “outperform” rating and set a $254.00 price target on shares of Danaher in a research report on Wednesday, January 28th. Morgan Stanley initiated coverage on Danaher in a report on Monday, December 1st. They issued an “overweight” rating and a $270.00 price objective for the company. Robert W. Baird set a $251.00 target price on Danaher in a report on Thursday, January 29th. Finally, HSBC lifted their target price on Danaher from $255.00 to $270.00 and gave the stock a “buy” rating in a research report on Monday, December 1st. Twenty analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $253.86.

Danaher Company Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that designs, manufactures and markets products and services for the life sciences, diagnostics, and environmental and applied markets. The company organizes its operations into business segments focused on Life Sciences, Diagnostics, and Environmental & Applied Solutions, supplying instruments, reagents, software and related services that support research, clinical testing, biopharmaceutical development, and industrial and environmental monitoring.

Products and services in Danaher’s portfolio include analytical and diagnostic instruments, laboratory consumables and reagents, digital and software solutions for workflow and data management, field and industrial monitoring equipment, and service and maintenance programs.